icone plus
Contact Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité TECENTRIQ (atezolizumab).
See also
Décision d'accès précoce
25/11/2022
eNrlWE1z2jAQvfMrGA69yQbzEWgNmZYmLTPJlJIw7fTCCHkBUSE5+gDSX18ZQ0M6prQCH9peGCPJb9fS27e7Ci/XC1ZcglRU8Hap4pVLReBERJRP26Xh/TVqli47hXCOl3hv2YVX9ipBqUgYVqpdSma9MWCuvM+3N2/Bvg+y1CkUQzGeA9HP1hlNmfceq9ktjpM1xXApaFRcgJ6JqF2Kjd6MFkOlpfWisxLyq4oxgdDfjuzPzke1/fHQT8B+A9UokDeYTzNBgTthEiMlcN3FGqZCPmZCxzKqjIJWs1FpNZ2MUDUAJYwk0Md61pdiSSOIMm1NMFPgZGSyiu5ALhnoxEgmuD8nC+UEjud4PYCHXrbTr+1sV681KqPKRaNeb7XqjYtGo+xkSu5tVTZ97Ef48ahabZUblcAH7kdAaMJyxINyEKByrVb3I+IrWKDIoKCGuFjCYiwBbebtGBGMwRRQBIhhNMNGA7I/QlK9GVSY24dYSG0fkISJUdu1ESwwt48RwoSAQrG0oUN2SCq2rmCWoGgglliSPjhSpp8YZzmRharuc+LnZEfCw1FSRlTFDD96cxW7bhWW2E6DtPKU34ckX3AvrWAyu2c/4XPDmP+HXg+3cpaTx4ladoWxFMxWteuB60Z0hQ2O9eETdRNivd5ykYI6H+w3wbOTUN+MGSWuSmu10IDSw0HvsND+Bxr1BisYyvxE6hPlkVip84vfPtly8n5zMOxIQVGvO8f2F8vsA/n4ykgRg29lkapT1K7HJ+JUnbPBkg21C5V/PUo2VasgmMGBuhU5KrENj12ZnVsA5hfc6UQm6Lure1fWfjQgH+82fzOhadT+wTe3NJVH7rMxcszxVE0S58v1Zqtae4EX8atdQ9R2bH5S0F/2PhMyCpoXtWbVrfMxMlsBZ1rH6qXvr1Yrb4ZVGqXeRP51ifMy82DOcTg2Sz1xLb+eMZdiLi1u0wyVk+vjtPT4M3a5ysqxcu/UFmb7/rZVyrShpYETziLNQLnlid7V+VPPU/+Sm9v9ZwKYn5lNr4G1VbG8ik0zzk4bJyU7e678WlqB+DCZ0AOXeQd5GfrpRWKnEPrJJWKn8B2aB9fZ
7GZ5vY1mTkMrYb4H
Listen
